Abvc Biopharma, INC 10-Q quarterly reports

ABVC BioPharma reported continued net losses and a working capital deficit in its Q2 2026 filing, raising substantial doubt about its going concern status.

ABVC BioPharma, Inc. reported a net loss of $1.69 million for the first quarter of 2026, a significant increase from the prior year's loss, with no revenue generated.

ABVC BioPharma posted an increased net loss in Q3 2025, driven by higher operating expenses, despite revenue growth and significant asset expansion through land acquisitions and debt reduction.

ABVC BioPharma reported a reduced net loss for the six months ended June 30, 2025, despite zero revenue, while addressing prior financial restatements and ongoing liquidity concerns.

ABVC BioPharma reports a net loss for Q1 2025 and discusses efforts to improve its financial position, including addressing a Nasdaq compliance issue and managing convertible debt.

ABVC BioPharma saw a significant increase in revenue and a substantial reduction in net loss for the third quarter of 2024, driven by licensing agreements and cost controls.

ABVC BioPharma's Q2 2024 results show increased revenue due to licensing agreements, but also a net loss due to increased operating and interest expenses.

ABVC BioPharma's first quarter 2024 results show a net loss of $3.98 million, a significant increase compared to the $1.90 million loss in the same period last year.